X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.clinicaltrialsarena.com/news/karyopharm-interim-eltanexor/
https://www.prnewswire.com/news-releases/karyopharm-announces-presentation-of-interim-data-from-phase-2-study-of-single-agent-eltanexor-in-relapsedrefractory-rr-higher-risk-myelodysplastic-neoplasms-mds-at-17th-international-congress-on-mds-301814640.html
https://www.prnewswire.com/news-releases/karyopharm-receives-orphan-drug-designation-from-fda-for-eltanexor-for-the-treatment-of-myelodysplastic-syndromes-301466251.html
https://investors.karyopharm.com/2021-10-21-Karyopharm-Announces-Dosing-of-First-Patient-in-a-Phase-2-Study-Investigating-Oral-Eltanexor-in-HMA-Refractory-Myelodysplastic-Syndrome
https://www.prnewswire.com/news-releases/antengenes-partner-karyopharm-therapeutics-announces-updated-data-of-eltanexor-in-patients-with-hypomethylating-agent-refractory-mds-301308428.html
https://www.prnewswire.com/news-releases/approval-of-phase-iii-clinical-trial-of-atg-016-eltanexor-a-second-generation-selective-inhibitor-of-nuclear-export-sine-in-mainland-china-for-the-treatment-of-myelodysplastic-syndrome-301180877.html
https://www.nasdaq.com/press-release/karyopharm-and-antengene-sign-exclusive-license-agreement-to-develop-and-commercialize-selinexor-20180524-00312
Market Place
Share 
